CD274 and non-small cell lung carcinoma: Subsequently, the advent of immunotherapy, specifically with the immune-checkpoint inhibitors (ICIs) targeting the programmed death receptor 1 (PD1) and its ligand (PD-L1), deeply impacted on the treatment management of several cancers, such as non-small cell lung cancer (NSCLC) and melanoma, as well as RCC, providing new therapeutic opportunities for the patients [7,8,9].